慢乙酰化者和快乙酰化者中肼屈嗪及其主要代谢物的动力学 - Suppr

Suppr

超能文献

Kinetics of hydralazine and its main metabolites in slow and fast acetylators.

作者信息

Reece P A, Cozamanis I, Zacest R

出版信息

Clin Pharmacol Ther. 1980 Dec;28(6):769-78. doi: 10.1038/clpt.1980.234.

DOI:10.1038/clpt.1980.234

PMID:7438692

Abstract

摘要

相似文献

Kinetics of hydralazine and its main metabolites in slow and fast acetylators.慢乙酰化者和快乙酰化者中肼屈嗪及其主要代谢物的动力学

Clin Pharmacol Ther. 1980 Dec;28(6):769-78. doi: 10.1038/clpt.1980.234.

Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.肼屈嗪诱发的类狼疮综合征患者的乙酰化酶表型

Acta Med Scand. 1976;200(5):367-71. doi: 10.1111/j.0954-6820.1976.tb08248.x.

Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?在为高血压患者开肼屈嗪处方时，是否应该确定乙酰化代谢表型？

Eur J Clin Pharmacol. 1984;26(1):39-42. doi: 10.1007/BF00546706.

Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.肯尼亚肯雅塔国家医院使用肼苯哒嗪治疗非洲高血压患者的乙酰化状态。

East Afr Med J. 1992 Jul;69(7):406-8.

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.肼屈嗪（一种抗高血压和DNA去甲基化剂）的药代动力学，使用基于乙酰化表型设计用于给药方案的控释制剂。

Int J Clin Pharmacol Ther. 2011 Aug;49(8):519-24. doi: 10.5414/cp201526.

Kinetics of hydralazine elimination.

Clin Pharmacol Ther. 1977 Jun;21(6):715-20. doi: 10.1002/cpt1977216715.

Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448.

Evaluation of once daily hydralazine in inadequately controlled hypertension.一日一次服用肼屈嗪治疗控制不佳的高血压的评估。

Acta Med Scand. 1983;214(5):373-80. doi: 10.1111/j.0954-6820.1983.tb08611.x.

Effect of oral dose size on hydralazine kinetics and vasodepressor response.口服剂量大小对肼屈嗪动力学和血管减压反应的影响。

Clin Pharmacol Ther. 1984 Nov;36(5):595-600. doi: 10.1038/clpt.1984.227.

Studies on hydralazine. III. Bioavailability of hydralazine in man.

Eur J Clin Pharmacol. 1976;10(6):395-401. doi: 10.1007/BF00563075.

引用本文的文献

Clinical review: the management of hypertensive crises.临床综述：高血压急症的管理

Crit Care. 2003 Oct;7(5):374-84. doi: 10.1186/cc2351. Epub 2003 Jul 16.

Individual variation in first-pass metabolism.首过代谢的个体差异。

Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.

Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.乙酰化表型对新型血管扩张性抗高血压药物恩屈嗪药代动力学的影响。

Eur J Clin Pharmacol. 1982;23(6):523-7. doi: 10.1007/BF00637500.

Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。

Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.

The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.恩屈嗪在原发性高血压患者和血压正常受试者中的药代动力学。

Br J Clin Pharmacol. 1983 Jul;16(1):27-32. doi: 10.1111/j.1365-2125.1983.tb02139.x.

Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.恩屈嗪，一种新型外周血管扩张剂。三年期间安全性和有效性评估。

Eur J Clin Pharmacol. 1983;24(3):301-5. doi: 10.1007/BF00610045.

Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.药物及其他外来化合物的药理活性代谢产物。临床、药理、治疗及毒理学考量。

Drugs. 1982 Dec;24(6):519-42. doi: 10.2165/00003495-198224060-00003.

Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.恩屈嗪——一种新型的类似肼屈嗪的具有高全身生物利用度的抗高血压药。

Eur J Clin Pharmacol. 1983;25(4):553-6. doi: 10.1007/BF00542127.

The effect of acetylator phenotype on the disposition of aminoglutethimide.乙酰化酶表型对氨鲁米特处置的影响。

Br J Clin Pharmacol. 1984 Oct;18(4):495-505. doi: 10.1111/j.1365-2125.1984.tb02497.x.

Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Eur J Clin Pharmacol. 1984;26(5):603-8. doi: 10.1007/BF00543493.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验